SolosEndoscopy, Inc. Successfully Completes FDA Inspection
BOSTON,March 3 /PINKSHEETS/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY - News)is pleased to announce that the Company has completed a Food and DrugAdministration (FDA) Level II Baseline Inspection and received a NAI (No ActionIndicated) for the inspection. It is standard for the FDA to periodicallyperform unannounced inspections for medical device manufacturers and thesuccessful inspection by the FDA validates the Company's quality system and itsstrict adherence to that system.
SolosEndoscopy's surgical product line is currently being used by surgeons andmedical technicians in hospitals and medical facilities across the country.Solos Endoscopy's MammoView(TM) was also recently featured in two surgicaltrade magazines, Surgical Products and Outpatient Surgery, whichis reflective of its growing popularity with the medical community.
"Successfulcompletion of the FDA Inspection also validates the hard work and dedication ofour employees and their commitment to patient safety, as well as providingsurgical instrumentation of the highest quality," stated Bob Segersten,President of Solos Endoscopy, Inc.
AboutSolos Endoscopy, Inc.:
SolosEndoscopy, Inc. is a healthcare technology company whose mission is to developand market breakthrough technology, applications, medical devices andprocedural techniques for the screening, diagnosis, treatment and management ofmedical conditions. Backed by technical support, Solos' sales team can helpmake the right buying decisions for the hospital, surgery center, or physicianoffice. Additional information is available on the Company's website at: www.solosendoscopy.com.
SafeHarbor: This release includes forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933 and Section 27E of the Securities Actof 1934. Statements contained in this release that are not historical facts maybe deemed to be forward-looking statements. Investors are cautioned thatforward-looking statements are inherently uncertain. Actual performance andresults may differ materially from that projected or suggested herein due tocertain risks and uncertainties including, without limitation, ability to obtainfinancing and regulatory and shareholder approval for anticipated actions.
Contact:
InvestorRelations
BigApple Consulting USA
1407-389-5900
SOURCE: Solos Endoscopy, Inc.